Cancer Genetics Hereditary Cancer Panel Testing (HCP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02324062 |
Recruitment Status :
Completed
First Posted : December 24, 2014
Last Update Posted : April 11, 2017
|
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date | December 14, 2014 | |||
First Posted Date | December 24, 2014 | |||
Last Update Posted Date | April 11, 2017 | |||
Actual Study Start Date | June 12, 2014 | |||
Actual Primary Completion Date | January 5, 2017 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures |
Develop Hereditary Cancer panel repository [ Time Frame: 3 years ] Develop a resource (repository and database) with banked specimens, HCP panel results, pre-clinical and follow up information and impact of the HCP results
|
|||
Original Primary Outcome Measures | Same as current | |||
Change History | ||||
Current Secondary Outcome Measures |
|
|||
Original Secondary Outcome Measures |
|
|||
Current Other Pre-specified Outcome Measures | Not Provided | |||
Original Other Pre-specified Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title | Cancer Genetics Hereditary Cancer Panel Testing | |||
Official Title | University of Southern California (USC) Norris Comprehensive Cancer Center and Stanford Cancer Institute Cancer Genetics Hereditary Cancer Panel Testing | |||
Brief Summary | This study is about understanding the use of a genetic test (Myriad Genetics myRisk panel) that analyzes 25 genes related to different hereditary cancer conditions. The investigators hope to learn more about how this type of genetic test is used clinically. The investigators also hope to understand more about the experience of individuals and families who undergoing this test of genetic testing. | |||
Detailed Description | If a patient is identified as fulfilling one of the screening criteria, possible participants should be referred to the Cancer Genetics Clinic for further evaluation for possible enrollment into the study. A pre-clinic questionnaire will be sent to the patients prior to their assessment in cancer genetics clinic in order to obtain baseline information that will be used to inform changes during follow-up. Assessments performed exclusively to determine eligibility for this study will be done only after obtaining informed consent. Assessments performed for clinical indications (not exclusively to determine study eligibility) may be used for baseline values even if the studies were done before informed consent was obtained. All screening procedures must be performed on the day of registration unless otherwise stated. The screening procedures include:
Intervention Procedure: Approximately 15 ml of blood will be drawn at the time of enrollment (one time blood draw) and sent to Myriad Genetics and Laboratories for analysis of 25 genes using next generation sequencing. This platform will sequence 25 genes in one experimental run and the results will be sent back to the cancer genetics clinic for interpretation and disclosure. Randomization of the patient Population: After results are given to the patient they will be randomized into 4 groups:
Stanford target accrual is 50 and 50 for USC.
Follow-up Procedures: Patients (as noted above) will be followed at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months • At 3 months and 6 months after disclosure of genetic testing results, follow up questionnaires will ask if participants had initiated or intend to undergo any of the following risk reducing interventions and/or treatment: (i) Cancer surveillance/screening: breast MRI, mammograms, self-breast examinations, thyroid ultrasound, dermatology exams, urinalysis, upper endoscopy, colonoscopy, endometrial biopsy, transvaginal ultrasound, or other imaging (i.e. whole body rapid MRI) (ii) Chemoprevention/Behavior Modification: Tamoxifen, Oral Contraceptives (OCP), Raloxifene, Sulindac, Abstinence from Smoking (iii) Prophylactic procedures: Mastectomy, TAHBSO, polypectomy, total and segmental colectomy (iv) Cancer Treatment: aggregated pharmacologic and radiation therapy. |
|||
Study Type | Observational | |||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
|||
Target Follow-Up Duration | Not Provided | |||
Biospecimen | Retention: Samples With DNA Description: Blood and Saliva
|
|||
Sampling Method | Non-Probability Sample | |||
Study Population | High-risk cancer genetics populations. Both male and female participants will be recruited. | |||
Condition | Hereditary Breast and Ovarian Cancer | |||
Intervention |
|
|||
Study Groups/Cohorts |
|
|||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status | Completed | |||
Actual Enrollment |
1511 | |||
Original Estimated Enrollment |
2000 | |||
Actual Study Completion Date | January 5, 2017 | |||
Actual Primary Completion Date | January 5, 2017 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria | Inclusion Criteria:Screening Criteria Patients meeting one of the following criteria will be eligible for screening the study.
Individuals with a pretest mutation probability of > 2.5% based on validated published models 15
Or one of the following: Individuals with a phenotypic diagnosis of the following recognized cancer genetic syndromes which automatically confers a clinical chance of > 2.5%:
Exclusion Criteria: Patients meeting one of the following criteria will be excluded the study
|
|||
Sex/Gender |
|
|||
Ages | Child, Adult, Older Adult | |||
Accepts Healthy Volunteers | No | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT02324062 | |||
Other Study ID Numbers | 0S-13-1 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement | Not Provided | |||
Current Responsible Party | University of Southern California | |||
Original Responsible Party | James Ford, Stanford University, Principle Investigator | |||
Current Study Sponsor | University of Southern California | |||
Original Study Sponsor | Stanford University | |||
Collaborators | Stanford University | |||
Investigators |
|
|||
PRS Account | University of Southern California | |||
Verification Date | April 2017 |